Inactive Instrument

Highlights Lightlake Therapeutics OTC Bulletin Board

Equities

US53224T1051

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2023	Indivior completes acquisition of Opiant Pharmaceuticals	AN
2023	Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Indivior completes acquisition of Opiant Pharmaceuticals	02/23/02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	02/23/02	MT
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	02/23/02	CI
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	08/23/08	MT
Indivior announces expiry of waiting period for Opiant purchase	06/23/06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	06/23/06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	06/23/06	MT
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	20/23/20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	20/23/20	CI
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug	23/22/23	MT
Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	23/22/23	CI
Indivior buys Opiant creating "comprehensive" treatment platform	14/22/14	AN
Opiant Pharmaceuticals to Be Acquired by Indivior	14/22/14	MT
Indivior to Acquire Opiant Pharmaceuticals For Initial $145 Million Consideration	14/22/14	MT
Opiant Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Indivior PLC entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. from a group of shareholders for approximately $110 million.	14/22/14	CI
Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder	06/22/06	CI
Opiant Pharmaceuticals Gets US Patent Allowance for OPNT004 to Treat Cannabinoid Hyperemesis Syndrome	23/22/23	MT
Earnings Flash (OPNT) OPIANT PHARMACEUTICALS Reports Q2 Revenue $3.9M, vs. Street Est of $4.66M	12/22/12	MT
Opiant Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lightlake Therapeutics OTC Bulletin Board

Equities

US53224T1051

Highlights

Filters